Mira Pharma Financials
This page shows Mira Pharma (MIRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Mira Pharma passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Mira Pharma generates $0.71 in operating cash flow (-$5.6M OCF vs -$7.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Mira Pharma reported -$7.9M in net income in fiscal year 2024. This represents an increase of 34.5% from the prior year.
Mira Pharma earned $-0.51 per diluted share (EPS) in fiscal year 2024. This represents an increase of 40.0% from the prior year.
Mira Pharma held $2.8M in cash against $0 in long-term debt as of fiscal year 2024.
Mira Pharma had 17M shares outstanding in fiscal year 2024. This represents an increase of 12.0% from the prior year.
Mira Pharma invested $3.3M in research and development in fiscal year 2024. This represents an increase of 110.1% from the prior year.
MIRA Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $413K-61.3% | $1.1M | N/A | $1.0M+1105.0% | -$101K-137.2% | $272K | N/A | $715K |
| SG&A Expenses | $904K-10.8% | $1.0M | N/A | $2.1M+100.2% | $1.1M+74.4% | $614K | N/A | $736K |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $16K+141.6% | -$38K | N/A | $428K+44.6% | $296K+17800.0% | $2K | N/A | $2K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.1M+44.3% | -$2.0M | N/A | -$3.6M-183.4% | -$1.3M+5.6% | -$1.3M | N/A | -$1.8M |
| EPS (Diluted) | $-1.18-742.9% | $-0.14 | N/A | $-0.26-160.0% | $-0.100.0% | $-0.10 | N/A | $-0.14 |
MIRA Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.6M+161.1% | $2.9M-40.7% | $4.9M-45.3% | $9.0M+135.8% | $3.8M | N/A | $858K | N/A |
| Current Assets | $7.6M+163.1% | $2.9M-40.6% | $4.9M-20.0% | $6.1M+1343.0% | $421K | N/A | $494K | N/A |
| Cash & Equivalents | $2.6M-6.8% | $2.8M-38.4% | $4.6M-21.6% | $5.9M+23540.7% | $25K | N/A | $351K | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | $5K | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $84K-88.4% | $723K+29.6% | $558K-38.2% | $903K-65.6% | $2.6M | N/A | $1.5M | N/A |
| Current Liabilities | $84K-88.4% | $723K+29.6% | $558K-35.7% | $868K-66.3% | $2.6M | N/A | $1.4M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.5M+243.2% | $2.2M-49.7% | $4.4M-46.1% | $8.1M+578.2% | $1.2M+166.9% | -$1.8M-200.1% | -$596K-286.1% | $320K |
| Retained Earnings | -$33.6M-15.3% | -$29.1M-36.9% | -$21.3M-37.3% | -$15.5M-30.1% | -$11.9M | N/A | -$9.3M | N/A |
MIRA Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M+39.2% | -$1.8M-74.4% | -$1.0M+41.2% | -$1.8M-166.5% | -$661K+38.5% | -$1.1M-10.2% | -$975K+25.8% | -$1.3M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $3.0M+509.6% | $493K+313.8% | -$231K-103.0% | $7.6M+1011.3% | $684K-5.7% | $726K-36.3% | $1.1M+68.4% | $676K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MIRA Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -14.9%+33.0pp | -47.9% | N/A | -39.8%-6.7pp | -33.1% | N/A | N/A | N/A |
| Current Ratio | 90.53+86.5 | 3.99-4.7 | 8.71+1.7 | 6.99+6.8 | 0.16 | N/A | 0.36 | N/A |
| Debt-to-Equity | 0.01-0.3 | 0.33+0.2 | 0.13+0.0 | 0.11-2.1 | 2.20 | N/A | -2.44 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Mira Pharma profitable?
No, Mira Pharma (MIRA) reported a net income of -$7.9M in fiscal year 2024.
What is Mira Pharma's earnings per share (EPS)?
Mira Pharma (MIRA) reported diluted earnings per share of $-0.51 for fiscal year 2024. This represents a 40.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Mira Pharma's operating cash flow?
Mira Pharma (MIRA) generated -$5.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Mira Pharma's total assets?
Mira Pharma (MIRA) had $2.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Mira Pharma spend on research and development?
Mira Pharma (MIRA) invested $3.3M in research and development during fiscal year 2024.
How many shares does Mira Pharma have outstanding?
Mira Pharma (MIRA) had 17M shares outstanding as of fiscal year 2024.
What is Mira Pharma's current ratio?
Mira Pharma (MIRA) had a current ratio of 3.99 as of fiscal year 2024, which is generally considered healthy.
What is Mira Pharma's debt-to-equity ratio?
Mira Pharma (MIRA) had a debt-to-equity ratio of 0.33 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mira Pharma's return on assets (ROA)?
Mira Pharma (MIRA) had a return on assets of -268.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Mira Pharma's cash runway?
Based on fiscal year 2024 data, Mira Pharma (MIRA) had $2.8M in cash against an annual operating cash burn of $5.6M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Mira Pharma's Piotroski F-Score?
Mira Pharma (MIRA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mira Pharma's earnings high quality?
Mira Pharma (MIRA) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.